Sign in Subscribe

microbiome

A collection of 15 issues

Network meta-analysis compares microbiota-modifying interventions for chemotherapy-related GI disorders

Skip to content The CRC Digest ♥ LIVING WITH CRC Network meta-analysis compares microbiota-modifying interventions for chemotherapy-related GI disorders Systematic review of randomized trials aimed to compare the effects of microbiota-modifying interventions, primarily probiotics and synbiotics, on gastrointestinal symptoms during chemotherapy in adults with CRC. (Semin Oncol Nurs) This content is

Propionate enhances CD8+ T-cell infiltration and immunotherapy response in preclinical models

Skip to content The CRC Digest ◇ RESEARCH Propionate enhances CD8+ T-cell infiltration and immunotherapy response in preclinical models A study using syngeneic MSI-H and MSS murine colorectal cancer models found that propionate, a short-chain fatty acid produced by gut microbiota, promoted CD8+ T-cell infiltration and enhanced efficacy when combined with

Gut Microbial Metabolites Screened for Role in Modulating PD-1/SHP-2 Interaction in MSS CRC

Skip to content The CRC Digest Gut Microbial Metabolites Screened for Role in Modulating PD-1/SHP-2 Interaction in MSS CRC Researchers established a screening system to identify gut microbiome-derived metabolites that may regulate anti-tumor immunity in microsatellite-stable colorectal cancer by modulating the PD-1/SHP-2 signaling pathway. (Journal for ImmunoTherapy of

Gut bacterium Eggerthella lenta linked to liver metastasis via vascular barrier disruption

Skip to content The CRC Digest ◇ RESEARCH Gut bacterium Eggerthella lenta linked to liver metastasis via vascular barrier disruption Multi-omics analysis of two cohorts comprising 20 healthy controls, 82 non-metastatic CRC patients, and 65 patients with liver or lung metastases found that those with CRC liver metastasis had impaired gut

Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer

Skip to content The CRC Digest ◇ RESEARCH Gut microbiome may influence resistance to immunotherapy in MSI-H/dMMR colorectal cancer A narrative review summarizes evidence that the gut microbiome-immune axis regulates antitumor immunity and may mediate both primary and acquired resistance to immune checkpoint inhibitors in MSI-H/dMMR CRC. (Front Cell

KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth

Skip to content The CRC Digest ◇ RESEARCH KRAS Mutation Enriches Gut Bacteria Linked to Tumor Growth A study in KRAS-mutant CRC patients and mice found that KRAS reshapes the microbial community, enriching Bacteroides acidifaciens, which predicts poor prognosis and promotes malignant phenotypes in KRAS-mutant tumors. (Cell Host & Microbe) This

Fusobacterium nucleatum Detected in 11% of Adenomas, Linked to Immune Signatures

Skip to content The CRC Digest ◇ RESEARCH Fusobacterium nucleatum Detected in 11% of Adenomas, Linked to Immune Signatures RNA-based detection found Fusobacterium nucleatum in 11% of adenoma tissue samples, with positive patients exhibiting enriched anti-bacterial defense response and immune-related transcriptomic signatures compared to negative patients. (International Journal of Molecular Sciences)

New Computational Model Predicts Drug Combinations That Account for Microbiome Effects

Skip to content The CRC Digest ◇ RESEARCH New Computational Model Predicts Drug Combinations That Account for Microbiome Effects Researchers developed a microbiome-aware framework combining machine learning and metabolic models to predict synergistic drug combinations for colorectal cancer in the presence of Fusobacterium nucleatum and other microbes. (Cell Rep Methods) This

Review links colibactin-producing E. coli to early-onset colorectal cancer through distinct mutational signatures

Skip to content The CRC Digest ◇ RESEARCH Review links colibactin-producing E. coli to early-onset colorectal cancer through distinct mutational signatures Genomic profiling has identified mutational signatures SBS88 and ID18 in colorectal tumors exposed to colibactin from pks+ E. coli, with emerging data suggesting enrichment in early-onset CRC. (Infection, Genetics and

Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders

Skip to content The CRC Digest ◇ RESEARCH Gut microbiome and metabolite profiles differ between immunotherapy responders and non-responders In 20 patients with MSI-H advanced colorectal cancer receiving immunotherapy, metagenomic sequencing and metabolomics revealed distinct gut microbiota and metabolite patterns associated with clinical benefit versus non-benefit, suggesting the microbiome may influence